Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  signal transduction inhibitor
Results 1-25 of 2135 for your search:
Start Over
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7501001, NCI-2014-01789, NCT02129205
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients with Progressive Meningiomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071401, NCI-2015-00546, NCI-2015-00501, NCT02523014
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371012, NCI-2015-00462, 2014-001345-24, NCT02367456
Pembrolizumab with or without Vismodegib in Treating Skin Basal Cell Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0031, NCI-2015-01869, 350, NCT02690948
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371003, NCI-2012-01145, 2012-000684-24, NCT01546038
Vismodegib in Treating Patients with Locally Advanced or Recurrent Orbital or Periocular Basal Cell Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2014.022, NCI-2015-00927, HUM00082579, ML29160, NCT02436408
Sonidegib and Everolimus in Treating Patients with Locally Advanced or Metastatic Gastroesophageal Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0838, NCI-2014-01455, NCT02138929
PF-04449913 in Treating Patients with Acute Leukemia or Myelodysplastic Syndromes at High Risk of Relapse after Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-1558, NCI-2013-00824, 12-1558.cc, COMIRB #12-1558, NCT01841333
Erismodegib in Treating Patients with High-Risk Localized Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1402, NCI-2014-02144, LDE225XUS13T, NA_00091602, NCT02111187
Erismodegib and Paclitaxel in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: UAB 1357, NCI-2015-01335, F140214007, NCT02195973
Itraconazole in Preventing Blood Vessel Growth in Patients with Non-small Cell Lung Cancer Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCCC-01515, NCI-2015-00458, 122014-038, Mod2_STU 122014-038, NCT02357836
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B1371013, NCI-2014-02538, 2014-000933-21, 2014-001048-40, SMOI, NCT02226172
Sonidegib and Buparlisib in Treating Patients with Advanced or Metastatic Basal Cell Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0020, NCI-2014-02200, 5136, NCT02303041
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: 52M51-001, NCI-2013-00503, NCT01703572
Azacitidine and Sonidegib or Decitabine in Treating Patients with Myeloid Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1389, NCI-2014-00866, Mod13-009003-08, NCT02129101
Itraconazole in Treating Patients with Basal Cell Carcinoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: J1299, NCI-2014-01255, NA_00077461, NCT02120677
Photodynamic Therapy and Vismodegib in Treating Patients with Multiple Basal Cell Cancers
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1511201549, NCI-2016-00096, ML28849, NCT02639117
Radiation Therapy and Vismodegib in Treating Patients With Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC #122011, NCI-2013-00871, 122011, NCT01835626
Sonidegib and Lenalidomide after Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC128B, NCI-2014-00170, NCT02086552
Smoothened Receptor Antagonist LY294068, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients with Localized Esophageal or Gastroesophageal Junction Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0966, NCI-2015-01554, NCT02530437
Sonidegib in Treating Patients with Advanced or Metastatic Liver Cancer That Cannot Be Removed by Surgery or Child-Pugh A/B7 Cirrhosis
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDE225XUS12T, NCI-2014-01762, 131053, HRPP #131053, NCT02151864
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Start Over